# Acumen Pharmaceuticals (ABOS) Stock Price, News & Analysis
Canonical URL: https://biopharmsignal.com/company/ABOS
## Company Profile
- Ticker: ABOS
- Exchange: NASDAQ
- Sector: Biopharma
- Location: United States
- Tags: CNS
## Stock Data
- Close: 2.47 USD
- Market cap: 171179364.6 USD
- Last updated: 2026-08-11
## Business Overview
### Alzheimer’s Disease Antibody Company
Acumen Pharmaceuticals develops therapies targeting soluble amyloid-beta oligomers, which are believed to contribute directly to synaptic dysfunction in Alzheimer’s disease.
### Sabirnetug
Sabirnetug is a monoclonal antibody designed to selectively bind toxic amyloid-beta oligomers while limiting interaction with monomers and plaques.
### Enhanced Brain Delivery
Acumen is also developing an enhanced brain-delivery platform intended to improve central nervous system exposure of future biologics.
## Why The Stock Is Moving

As of Aug 11, 2026, ABOS closed up 1.65% at $2.47. No new same-company headline was identified in the current news window.

## Future Catalysts

- Topline results from the Phase 2 ALTITUDE-AD study of sabirnetug are expected in late 2026.
- An IND filing for the lead enhanced brain-delivery candidate is targeted for mid-2027.

## Recent News
- 2026-08-05 20:00 EST — [Acumen Pharmaceuticals to Report Second Quarter Financial Results on August 12, 2026](https://biopharmsignal.com/news/ABOS/acumen-pharmaceuticals-to-report-second-quarter-financial-results-on-august-12-2-464ebfdf) — Source: Acumen Pharmaceuticals
- 2026-07-15 11:30 EST — [Acumen Pharmaceuticals Highlights Enhanced Brain Delivery™ (EBD™) Program Data and Early Alzheimer’s Disease Insights at the Alzheimer’s Association International Conference (AAIC®) 2026](https://biopharmsignal.com/news/ABOS/acumen-pharmaceuticals-highlights-enhanced-brain-delivery-ebd-program-data-and-e-12dd8779) — Source: Acumen Pharmaceuticals
- 2026-07-07 11:30 EST — [Acumen Pharmaceuticals to Present Data on Enhanced Brain Delivery™ (EBD™) Technology and Early Alzheimer’s Disease Insights at the Alzheimer’s Association International Conference (AAIC®) 2026](https://biopharmsignal.com/news/ABOS/acumen-pharmaceuticals-to-present-data-on-enhanced-brain-delivery-ebd-technology-95eca401) — Source: Acumen Pharmaceuticals
- 2026-06-16 11:30 EST — [Acumen Pharmaceuticals Announces Nomination of Two Enhanced Brain Delivery™ (EBD™) Development Candidates for the Treatment of Alzheimer’s Disease](https://biopharmsignal.com/news/ABOS/acumen-pharmaceuticals-announces-nomination-of-two-enhanced-brain-delivery-ebd-d-d74b8122) — Source: Acumen Pharmaceuticals
- 2026-05-12 11:00 EST — [Acumen Pharmaceuticals Reports First Quarter 2026 Financial Results and Business Highlights](https://biopharmsignal.com/news/ABOS/acumen-pharmaceuticals-reports-first-quarter-2026-financial-results-and-business-ba885971) — Source: Acumen Pharmaceuticals